Adoptive t-cell therapy for Epstein-Barr virus-positive Hodgkin's disease

Acta Haematologica

Volumn 110, Issue 2-3, 2003, Pages 149-153

  Huls, M Helen ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Adoptive immunotherapy; Cytotoxic T lymphocyte; Epstein Barr virus; Hodgkin's disease

Indexed keywords

ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; BIOSAFETY; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER INVASION; CLINICAL FEATURE; CYTOTOXICITY; DNA MODIFICATION; EPSTEIN BARR VIRUS; FOLLOW UP; GENETIC CODE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION;

ADOPTIVE TRANSFER; EPSTEIN-BARR VIRUS INFECTIONS; HODGKIN DISEASE; HUMANS; T-LYMPHOCYTES;

EID: 0242299673     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072464     Document Type: Review

References (32)

1. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphopro-liferation. Lancet 1995;345:9-13.
2. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Ep-stein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
3. Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y-J, Srivastava D-K, Bowman LC, Krance RA, Brenner MK, Heslop HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
4. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95: 807-814.
5. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:405-431.
6. Raab-Traub N: Epstein-Barr virus and naso-pharyngeal carcinoma. Semin Cancer Biol 1992;3:297.
7. Weiss LM, Movahed LA, Warnke RA, Sklar J: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-506.
8. Beaty O, Hudson MM, Greenwald C, Luo X, Fang L, Wilimas JA, Thompson EI, Kun LE, Pratt CB: Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995;13:603-609.
9. Herbst H, Dallenback F, Hummel M, Niedobitek G, Pileri S, Nuller-Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Aci USA 1991;88:4766-4770.
10. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375: 685-688.
11. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI: The impact of Hodgkin's disease on the immune system. Semin Oncol 1990;17:673-682.
12. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M: T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996;88:236-241.
13. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Lee Park SY, Watanabe M, Gong JL, Hayes DF, Kufe DW, Nadler LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996;2: 1367-1370.
14. Smith CA, Ng CYC, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM: Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995;4:73-79.
15. Roskrow MA, Suzuki N, Gan Y-J, Sixbey JW, Ng CYC, Kimbrough S, Hudson MM, Brenner MK, Heslop HE, Rooney CM: EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood 1998;91:2925-2934.
16. Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum G: Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther 1998;9:1237-1250.
17. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD: Isolation of Epstein-Barr Virus (EBV)-specific cyto-toxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-medicated therapy of EBV Hodgkin's disease. Blood 1997;89: 1978-1986.
18. Khanna R, Burrows SR, Nicholls J, Poulsen LM: Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998; 28:451-458.
19. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS: Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996;88: 3491-3501.
20. Trivedi P, Hu LF, Christensson B, Masucci MG, Klein G, Winberg G: Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 1994; 30A:84-88.
21. Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop H, Aguilar-Cordova E, Rooney C: Ade-noviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001;93:706-713.
22. Su Z, Peluso MV, Raffegerst SH, Schendel DJ, Roskrow MA: The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947-958.
23. Redchenko IV, Rickinson AB: Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol 1999;73: 334-342.
24. Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ: Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vaccination. J Virol 1999;73:10416-10425.
25. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI: Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol 2001;98:220-228.
26. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F: Hodgkin's disease: A tumor with disturbed immunological pathways. Immunol Today 1997;18:156-163.
27. Pardoux C, Ma X, Gobert S, Pellegrini S, Mayeux P, Gay F, Trinchieri G, Chouaib S: Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: Relationship with IL-12 signaling. Blood 1999;93:1448-1455.
28. Ranges GE, Figari IS, Espevik T, Palladino MA Jr: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987;166:991-998.
29. Graus F, Gultekin SH, Ferrer I, Reiriz J, Alberch J, Dalmau J: Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol (Berl) 1998;96: 1-7.
30. Seo N, Tokura Y: Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res 1999;19:555-561.
31. Sallusto F, Lenig D, MacKay CR, Lanzavecchia A: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-883.
32. van den Berg A, Visser L, Poppema S: High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691.